These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16019526)

  • 1. The role of rHuEpo in low-risk myelodysplastic syndrome patients.
    Rigolin GM; Castoldi G
    Leuk Lymphoma; 2005 Jun; 46(6):823-31. PubMed ID: 16019526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
    Casadevall N; Durieux P; Dubois S; Hemery F; Lepage E; Quarré MC; Damaj G; Giraudier S; Guerci A; Laurent G; Dombret H; Chomienne C; Ribrag V; Stamatoullas A; Marie JP; Vekhoff A; Maloisel F; Navarro R; Dreyfus F; Fenaux P
    Blood; 2004 Jul; 104(2):321-7. PubMed ID: 15054036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples.
    Rigolin GM; Porta MD; Bigoni R; Cavazzini F; Ciccone M; Bardi A; Cuneo A; Castoldi G
    Br J Haematol; 2002 Dec; 119(3):652-9. PubMed ID: 12437640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic growth factors in myelodysplastic syndromes.
    Blinder VS; Roboz GJ
    Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.
    Rigolin GM; Porta MD; Ciccone M; Bugli AM; Bragotti LZ; Mauro E; Fraulini C; Rossi AR; Bardi A; Cuneo A; Castoldi G
    Br J Haematol; 2004 Aug; 126(4):501-7. PubMed ID: 15287942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.
    Affentranger L; Bohlius J; Hallal M; Bonadies N
    Crit Rev Oncol Hematol; 2019 Apr; 136():37-47. PubMed ID: 30878127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.
    Miller K
    Leuk Res; 1998 May; 22 Suppl 1():S13-6. PubMed ID: 9734694
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges.
    Stasi R; Amadori S; Newland AC; Provan D
    Blood; 2004 Oct; 104(7):2201; author reply 2201-2. PubMed ID: 15377575
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
    Nagler A; Ginzton N; Negrin R; Bang D; Donlon T; Greenberg P
    Leukemia; 1990 Mar; 4(3):193-202. PubMed ID: 1690318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors.
    Merchav S; Wagemaker G; Souza LM; Tatarsky I
    Leukemia; 1991 Apr; 5(4):340-6. PubMed ID: 1709245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The place of growth factors in the treatment of myelodysplastic syndromes].
    Ugo V; Casadevall N
    Pathol Biol (Paris); 2002 May; 50(4):268-74. PubMed ID: 12085672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of in vivo treatment with rh GM-CSF on in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes.
    Visani G; Tosi P; Finelli C; Gamberi B; Zauli G; Cenacchi A; Fogli M; Colombini R; Tura S
    Haematologica; 1992; 77(2):142-5. PubMed ID: 1383105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
    Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V
    Clin Cancer Res; 2012 Jun; 18(11):3079-89. PubMed ID: 22496271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.